NRAS Q61R and BRAF G466A mutations in atypical melanocytic lesions newly arising in advanced melanoma patients treated with vemurafenib. [electronic resource]
Producer: 20190523Description: 190-194 p. digitalISSN:- 1600-0560
- Aged, 80 and over
- Antineoplastic Agents -- adverse effects
- Female
- GTP Phosphohydrolases -- genetics
- Humans
- Male
- Melanoma -- drug therapy
- Membrane Proteins -- genetics
- Mutation
- Neoplasms, Second Primary -- chemically induced
- Proto-Oncogene Proteins B-raf -- genetics
- Retrospective Studies
- Skin Neoplasms -- chemically induced
- Vemurafenib -- adverse effects
- Melanoma, Cutaneous Malignant
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.